DG DISPATCH - WCO: Fosamax Can Be Taken Before Lunch or Dinner
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - WCO: Fosamax Can Be Taken Before Lunch or Dinner

By W. A. Thomasson, PhD
Special to DG News

CHICAGO, IL -- June 19, 2000 -- Official dosing directions for Fosamax (alendronate sodium) require it to be taken a half-hour to an hour before breakfast, a regimen that many patients find extremely inconvenient.

Data presented yesterday (June 18) at the World Congress on Osteoporosis, however, suggest this may not be necessary: Results showed that equivalent effects are obtained when the medication is taken an hour before lunch or dinner.

Pierre Delmas, MD, of Claude Bernard University in Lyon, France, and colleagues enrolled 139 post-menopausal women with osteoporosis and randomly assigned them to 10 mg daily dose of Fosamax either half an hour before breakfast, one hour before lunch, or one hour before dinner.

Those women taking the doses before lunch or dinner were required to take them at least four hours after their previous meal.

Biochemical markers of bone turnover were measured at three months and at six months, with approximately the same decrease from baseline being seen in all three groups.

The only statistically significant differences were seen in patients taking their dose before dinner, where there was a smaller decrease in one marker at three months and in another marker at six months. The decrease from baseline was statistically significant in all cases. Approximately 90 percent of the patients in each group were classified as responding to Fosamax.

Critical data comparing effects on bone mineral density are not yet available, since they will be obtained at one-year follow-up. Fracture data will likewise require longer follow-up and perhaps a larger study.

Nevertheless, the biochemical data encourage hope that patients may soon have a more convenient Fosamax dosing regimen available to them.

Related Link: Fosamax (alendronate sodium).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities